MC
Therapeutic Areas
Boston Scientific Pipeline
| Drug | Indication | Phase |
|---|---|---|
| FARAPULSE PFA System | Atrial Fibrillation | FDA Approved |
| AGENT DCB | Coronary In-Stent Restenosis | FDA Approved |
| Ranger DCB | Peripheral Artery Disease | Pivotal Trial |
| ACURATE neo2 | Aortic Stenosis (TAVI) | Pivotal Trial |
Leadership Team at Boston Scientific
MF
Michael F. Mahoney
Chairman and Chief Executive Officer
DJ
Daniel J. Brennan
Executive Vice President and Chief Financial Officer
JM
Joseph M. Fitzgerald
Executive Vice President and President, MedSurg
WC
Wendy Carruthers
Executive Vice President and President, Rhythm Management & Neuromodulation
DI
Dr. Ian T. Meredith
Executive Vice President and Global Chief Medical Officer